AbbVie’s (ABBV) Buy Rating Reiterated at Guggenheim

AbbVie (NYSE:ABBV)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a research report issued on Friday, Benzinga reports. They currently have a $288.00 target price on the stock. Guggenheim’s price target would indicate a potential upside of 4.49% from the stock’s current price.

ABBV has been the topic of a number of other reports. Royal Bank Of Canada upped their price objective on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a report on Tuesday. Cantor Fitzgerald upped their price objective on AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday. Bank of America reiterated a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Finally, Canaccord Genuity Group upped their target price on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $276.64.

AbbVie Trading Up 1.2%

Shares of NYSE:ABBV traded up $3.21 during trading on Friday, hitting $275.63. 268,591 shares of the company were exchanged, compared to its average volume of 6,397,650. The stock has a market cap of $486.98 billion, a price-to-earnings ratio of 77.95, a P/E/G ratio of 1.23 and a beta of 0.24. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $275.87. The firm has a fifty day moving average price of $258.56 and a two-hundred day moving average price of $236.35.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts predict that AbbVie will post 14.01 EPS for the current year.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AbbVie

Institutional investors and hedge funds have recently made changes to their positions in the stock. Burk Holdings LLC acquired a new stake in AbbVie during the second quarter worth approximately $30,000. Abound Financial LLC acquired a new stake in AbbVie during the fourth quarter worth approximately $32,000. Merkkuri Wealth Advisors LLC acquired a new stake in AbbVie during the first quarter worth approximately $34,000. Marquette Asset Management LLC grew its stake in AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the period. Finally, Phillip James Consulting Co. acquired a new stake in AbbVie during the fourth quarter worth approximately $36,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts raised targets and reaffirmed bullish ratings. Guggenheim reaffirmed its “buy” rating with a $288 price target, while JPMorgan raised its target to $300 and maintained an “overweight” rating. Cantor Fitzgerald also lifted its target to $290 and kept an “overweight” rating. The revisions indicate continued confidence in AbbVie’s earnings outlook and growth prospects.
• Positive Sentiment: Temab-A received two FDA Breakthrough Therapy Designations. AbbVie’s telisotuzumab adizutecan (Temab-A, or ABBV-400) received the designations for potential use in colorectal cancer and non-small cell lung cancer. The FDA status may accelerate development and review, strengthening the perceived value of AbbVie’s oncology pipeline. FDA Grants Breakthrough Therapy Designations to AbbVie’s Temab-A
• Positive Sentiment: Additional oncology data supported pipeline optimism. An AbbVie and Genmab combination involving epcoritamab reportedly reduced the risk of progression or death by 51% in diffuse large B-cell lymphoma, providing another favorable signal for AbbVie’s cancer portfolio.
• Positive Sentiment: Momentum has pushed ABBV to new one-year highs. The stock recently set consecutive 52-week highs, suggesting that analyst upgrades and pipeline news are reinforcing positive investor sentiment.
• Neutral Sentiment: Valuation and expectations remain important risks. AbbVie is trading near its 12-month high with a relatively elevated price-to-earnings ratio, so further gains may depend on the company delivering against strong earnings and pipeline expectations. Recent coverage also noted mixed growth outlooks across large pharmaceutical companies, despite higher price targets.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.